Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site
Aclarion added the University of Arizona College of Medicine – Phoenix as a new clinical site for its CLARITY trial, bringing the total number of active enrollment sites to ten. The CLARITY trial is a 300-patient, prospective, randomized study evaluating Nociscan's ability to improve surgical outcomes for chronic low back pain, with primary endpoints measuring pain reduction at 12 months.
Key figures
- Trial patients target
- 300
- Trial sites enrolling
- 10
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.